Почетна › Рак јајника › Тексас › Houston
Kliničke studije za Рак јајника u gradu Houston, TX
90 studija za Рак јајника traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Тражи се учесник
- M D Anderson Cancer Center, Houston
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
Тражи се учесникФаза 1/2
- NEXT Houston, Houston
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Тражи се учесникФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Тражи се учесникФаза 2
- Lyndon Baines Johnson General Hospital, Houston
- UT MD Anderson Cancer Center, Houston
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Тражи се учесникФаза 3
- Houston Methodist Hospital, Houston
- Memorial Hermann Texas Medical Center, Houston
- Methodist Willowbrook Hospital, Houston
- и још 1
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Тражи се учесникФаза 1
- Site 0103, Houston
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Тражи се учесник
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- Memorial Hermann Texas Medical Center, Houston
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Тражи се учесникОпсервациона студија
- Total Women's Care of the Heights, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Тражи се учесникФаза 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Тражи се учесникФаза 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Тражи се учесникФаза 1
- Baylor College of Medicine, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Тражи се учесникФаза 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Тражи се учесникФаза 2
- Site 0103 - University of Texas MD Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 2
- USA12-0, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Тражи се учесникФаза 1
- MD Anderson, Houston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Тражи се учесникФаза 2/3
- Houston Methodist Hospital, Houston
- University of Texas - MD Anderson, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Тражи се учесникФаза 2
- Houston Methodist Hospital /ID# 274568, Houston
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Тражи се учесникФаза 3
- Research Site, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Тражи се учесник
- Lyndon Baines Johnson General, Houston
- M D Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Тражи се учесникФаза 1
- Oncology Consultants, Houston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Тражи се учесникФаза 1/2
- Research Site, Houston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
Тражи се учесникЗдраве особе су добродошле
- University of Texas MD Anderson Cancer Center, Houston
- Women's Hospital of Texas, Obstetrics and Gynecology Associates (OGA), Houston
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Тражи се учесникФаза 2
- MD Anderson Cancer Center, Houston
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
Тражи се учесник
- M D Anderson Cancer Center, Houston
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Тражи се учесникФаза 1/2
- Research Site, Houston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Тражи се учесникФаза 1/2
- Research Site, Houston
A Study of PHST001 in Advanced Solid Tumors
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Тражи се учесникФаза 1
- Research Site, Houston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Тражи се учесникФаза 2
- Research Site, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Тражи се учесникФаза 1/2
- MD Anderson, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Тражи се учесникФаза 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Тражи се учесникФаза 3
- Lyndon Baines Johnson General, Houston
- Houston Methodist, Houston
- M D Anderson Cancer Center, Houston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- M. D. Anderson Cancer Center, Houston
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Тражи се учесникФаза 3
- Baylor College of Medicine, Houston
- University of Texas Science Center at Houston, McGovern Medical School, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Тражи се учесникФаза 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Тражи се учесникФаза 1
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Houston Methodist Hospital, Houston
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Тражи се учесникФаза 2
- M D Anderson Cancer Center, Houston
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Тражи се учесникОпсервациона студија
- M D Anderson Cancer Center, Houston
A Study of DM002 in Patients With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- NEXT - Oncology - Houston, Houston
IDOV-Immune for Advanced Solid Tumors
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
Тражи се учесник
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Тражи се учесникФаза 2
- University of Texas MD Anderson Cancer Center, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Тражи се учесникФаза 1/2
- MD Anderson, Houston
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Тражи се учесникФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Тражи се учесникФаза 2
- Memorial Hermann Texas Medical Center /ID# 272227, Houston
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Тражи се учесникФаза 1/2
- Research site, Houston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Тражи се учесникФаза 1/2
- University of Texas MD Anderson Cancer Center, Houston
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Тражи се учесникФаза 3
- Baylor College of Medicine Medical Center, Houston
- O'Quinn Medical Tower at McNair Campus, Houston
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Тражи се учесник
- Harris Health Lyndon B. Johnson Hospital, Houston
- MD Anderson Cancer Centre, Houston
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
Тражи се учесник
- Dan L Duncan Comprehensive Cancer Center at the O'Quinn Medical Tower at Baylor St. Luke's Medical Center, Houston
- Harris Health Smith Clinic, Houston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Тражи се учесникФаза 1/2
- Oncology Consultants, Houston
- Next Oncology, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Тражи се учесникФаза 2
- Houston Methodist Neal Cancer Center, Houston
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Тражи се учесникФаза 1
- M D Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Тражи се учесникФаза 1
- MD Anderson Cancer Center, Houston
- NEXT Oncology, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- MD Anderson Cancer Center, Houston
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Тражи се учесникФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Тражи се учесникФаза 1
- The University of Texas M.D. Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Тражи се учесникЗдраве особе су добродошле
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
Studije za Рак јајника u drugim gradovima
- New York City, NY75 студија
- Boston, MA62 студија
- Los Angeles, CA53 студија
- Nashville, TN50 студија
- Arlington, VA47 студија
- Philadelphia, PA47 студија
- Columbus, OH39 студија
- St. Louis, MO37 студија
- Chicago, IL36 студија
- San Antonio, TX33 студија
- Pittsburgh, PA32 студија
- Dallas, TX31 студија
Ostale studije u gradu Houston
- Немалоклетни карцином плућа143 студија
- Рак дојке126 студија
- Рак (све врсте)124 студија
- Колоректални карцином101 студија
- Метастатски карцином100 студија
- Akutna mijeloidna leukemija88 студија
- Рак плућа78 студија
- Рак простате73 студија
- Карцином ендометријума69 студија
- Меланом61 студија
- Рак панкреаса59 студија
- Плоскоклеточни карцином главе и врата49 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.